Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
obrixtamig
- Development stage
- Phase 3
- Lead developer
- Boehringer Ingelheim
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Obrixtamig is a bispecific T-cell engager antibody that targets both delta-like ligand 3 (DLL3), a tumor-associated antigen highly expressed in certain neuroendocrine tumors and small cell lung cancer (SCLC), and CD3 on cytotoxic T lymphocytes. By binding to DLL3 on tumor cells and CD3 on T cells, obrixtamig redirects the immune system to recognize and kill DLL3-expressing cancer cells through immunologic cytotoxicity. It is being developed primarily for the treatment of SCLC, extrapulmonary neuroendocrine carcinomas (epNEC), large cell neuroendocrine carcinoma of the lung (LCNEC-L), glioma, and other neuroendocrine carcinomas. Obrixtamig has received orphan drug designation for SCLC and is administered intravenously[1][2][5][7][8].
- Brand names
- obrixtamig
- Other names
- DLL3/CD3 T-cell engageranti-DLL3/CD3 bispecific antibody BI 764532
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on obrixtamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on obrixtamig.